α‐ketoglutarate dehydrogenase in alzheimer brains bearing the APP670/671 mutation

Alzheimer's disease (AD) is associated with a striking reduction in the activity of the α‐ketoglutarate dehydrogenase complex (KGDHC). The deficiency occurs in brains from AD patients of undefined etiology, and in fibroblasts from both sporadic and familial AD cases. To further assess the nature of the abnormality of KGDHC in AD, KGDHC activities and immunoreactivities were analyzed in brains from AD patients bearing the Swedish APP670/671 mutation. This gene defect causes overproduction of the amyloid β peptide. KGDHC activities were reduced by 55 to 57% compared with control values in the mutation‐bearing AD cases in the medial temporal and superior frontal cortices. The immunochemical levels of KGDHC subunits E1k (−51%) and E2k (−76%) declined, whereas E3 concentrations were unchanged. The results suggest that mitochondrial dysfunction is a part of the pathophysiological process in AD even when the primary pathogenic cause is nonmitochondrial.

[1]  B. Winblad,et al.  Increased β‐amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer's disease APP670/671 mutation , 1994, FEBS letters.

[2]  J. Blass,et al.  Abnormality of the α‐ketoglutarate dehydrogenase complex in fibroblasts from familial Alzheimer's disease , 1994 .

[3]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[4]  J. Lindsay,et al.  Immunological and biosynthetic studies on the mammalian 2-oxoglutarate dehydrogenase multienzyme complex. , 1986, European journal of biochemistry.

[5]  S. Kish,et al.  Cerebellar α‐Ketoglutarate dehydrogenase activity is reduced in spinocerebellar ataxia type 1 , 1994 .

[6]  L. Reed,et al.  Structure-function relationships in dihydrolipoamide acyltransferases. , 1990, The Journal of biological chemistry.

[7]  J. Blass,et al.  Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. , 1988, Archives of neurology.

[8]  D. Alkon,et al.  Abnormalities in Alzheimer’s Disease Fibroblasts Bearing the APP670/671 Mutation , 1997, Neurobiology of Aging.

[9]  G. Gibson,et al.  Distribution of the α‐ketoglutarate dehydrogenase complex in rat brain , 1994, The Journal of comparative neurology.

[10]  T. Yanagihara,et al.  Alzheimer-type pathology in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) , 1996, Acta Neuropathologica.

[11]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[12]  H. Joenje,et al.  Hyperoxia-induced clonogenic killing of HeLa cells associated with respiratory failure and selective inactivation of Krebs cycle enzymes. , 1990, Mutation research.

[13]  N. Hattori,et al.  Role of mitochondria in the etiology and pathogenesis of Parkinson's disease. , 1995, Biochimica et biophysica acta.

[14]  J. Hardy,et al.  Amyloid precursor protein mutation causes Alzheimer's disease in a Swedish family , 1994, Neuroscience Letters.

[15]  S. Ohta,et al.  Alzheimer's disease and DLST genotype , 1997, The Lancet.

[16]  P. Matsudaira,et al.  Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. , 1994, The Journal of biological chemistry.

[17]  J. Lindsay,et al.  Immunochemical Characterization of the Deficiency of the α‐Ketoglutarate Dehydrogenase Complex in Thiamine‐Deficient Rat Brain , 1998, Journal of neurochemistry.

[18]  B. Winblad,et al.  Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Lai,et al.  Brain α‐Ketoglutarate Dehydrogenase Complex: Kinetic Properties, Regional Distribution, and Effects of Inhibitors , 1986, Journal of neurochemistry.

[20]  B. Winblad,et al.  A large Swedish family with Alzheimer's disease with a codon 670/671 amyloid precursor protein mutation. A clinical and genealogical investigation. , 1994, Archives of neurology.

[21]  S. Rapoport,et al.  Evidence for Physiological Down-regulation of Brain Oxidative Phosphorylation in Alzheimer's Disease , 1996, Experimental Neurology.

[22]  Piero Antuono,et al.  Cytochrome oxidase in Alzheimer's disease: Biochemical, histochemical, and immunohistochemical analyses of the visual and other systems , 1997, Vision Research.

[23]  S. Kish,et al.  Brain protein and α‐ketoglutarate dehydrogenase complex activity in alzheimer‐s disease , 1996, Annals of neurology.

[24]  L. Iversen,et al.  Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Hunter,et al.  Low immunogenicity of the common lipoamide dehydrogenase subunit (E3) of mammalian pyruvate dehydrogenase and 2-oxoglutarate dehydrogenase multienzyme complexes. , 1985, The Biochemical journal.

[26]  A. Hofman,et al.  Mutation analysis of the chromosome 14q24.3 dihydrolipoyl succinyltransferase (DLST) gene in patients with early-onset Alzheimer disease , 1995, Neuroscience Letters.

[27]  S. Kish,et al.  Brain thiamine, its phosphate esters, and its metabolizing enzymes in alzheimer's disease , 1996, Annals of neurology.

[28]  S. Kish,et al.  Brain α‐Ketoglutarate Dehydrotenase Complex Activity in Alzheimer's Disease , 1993 .